Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Why Generic EpiPen Is Not The Answer – Until FDA Says It Is

Aug 29 2016

• By Michael McCaughan

EpiPen 2-pak

Related Content

Mylan Could Get Out Of EpiPen Price Backlash With A Little Contrition, Analyst Says

Aug 25 2016

Eye Of The Pricing Storm: FDA's Woodcock Withstands Gale-Force Rhetoric

Feb 08 2016

Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL

Mar 01 2016

Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact

Mar 21 2016

Related Companies

Viatris Inc.

Vyera Pharmaceuticals, LLC

Teva Pharmaceutical Industries Ltd.

DMK Pharmaceuticals Corp.

Sanofi

Additional Topics

United States Regulation Policy Pricing Debate BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window